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Abstract  
Background: There is uncertainty about the most important indicators of pulmonary 
exacerbations in CF. Methods: Two parallel Delphi surveys in 13 CF centres (UK and 
Ireland). Delphi 1: 31 adults with CF, ≥ one exacerbation over 12 months. Delphi 2: 38 CF 
health professionals. Rounds 1 and 2 participants rated their level of agreement with 
statements relating to indicators of exacerbation; Round 3 participants rated the importance 
of statements which were subsequently placed in rank order. Results: Objective 
measurements were of higher importance to health professionals. Feelings of increased 
debility were rated most important by adults with CF. Conclusions: There were clear 
differences in perspectives between the two groups as to the most important indicators of an 
exacerbation. This highlights that CF health professionals should take more cognisance of  
specific signs and symptoms reported by adults with CF, especially since these  may be a 
precursor to an exacerbation.  
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1. Introduction  
  
 Pulmonary exacerbations (PEX) in cystic fibrosis (CF) are associated with disease 
progression, increased morbidity, mortality, and substantial healthcare costs [1-4]. PEX are 
experienced by a large proportion of patients with CF. The most recent annual information 
from the CF Registry of Ireland reported 451 paediatric admissions and 680 adult 
admissions for a PEX treated with intravenous antibiotics, using data that was available for 
881 of registered patients [5]. The CF Registry of the UK reported 3732 paediatric lung 
infections and 5062 adult lung infections using data that was available for 8794 registered 
patients [6]. Minimising PEXs is critical for the long term health of adults with CF since 
patients who have more than two PEX per year have a significantly reduced three year 
survival compared to those who have one or none [4]. PEXs are associated with a more 
rapid decline in FEV1, which results in a further decline in overall wellbeing [7, 8].  Health 
related quality of life (HRQoL) worsens during PEX and more severe exacerbations have a 
greater negative impact on HRQoL [1, 8]. Most people with CF die of respiratory failure 
which has typically been induced by a PEX [9, 10, 11].  
PEXs are also frequently used as an end point in clinical trials and recommended by 
European Medicines Agency (EMA) and Food and Drug Administration (FDA) as primary 
efficacy end points [2, 12, 13, 14]. However, neither agency mandates any definition of a 
PEX. Consequently definitions used in clinical trials are multiple and are inconsistent with 
each other [15]. In addition, they often show inconsistencies with criteria routinely used by 
CF health professionals [16-18].  
Previously it was suggested that the Delphi technique is an appropriate methodology 
to identify which criteria should be included in a definition of a PEX in CF [17].  This 
technique uses a series of repeated surveys to gain consensus on a given issue [19-22].  
This method reduces peer pressure and encourages unbiased responses, as 
participants remain anonymous to the core members of the research team and to other 
participants [19, 21-23]. The Delphi technique is a practical, efficient, inexpensive and widely 
used consensus research method in health care research [24, 25].  
The aim of this study was to identify the important indicators of an exacerbation 
determined by a group of adults with CF and a group of CF health professionals.  
 
2. Methods 
 
2.1 Design and recruitment  
  
Two parallel Delphi surveys were used to investigate agreement among a group of 
adults with CF and CF health professionals regarding the important indicators of an 
exacerbation.  
This was a multicentre study across the UK and Ireland. Twenty-seven CF centres 
were approached to take part aiming to recruit two to three adults with CF and two to three 
CF health professionals per centre. Participants were identified by a designated key health 
professional at each CF centre who was responsible for ensuring all participants met the 
inclusion criteria for their participant group. The inclusion criteria for adults with CF were: 
confirmed diagnosis of CF, over 18 years, FEV1 less than or equal to 80% predicted, 
experienced at least one exacerbation requiring IV antibiotics in the previous 12 months and 
computer literate with internet access available for the duration of the study. The inclusion 
criteria for CF Health Professionals were: CF health professionals working in adult CF 
centres in the UK/Ireland, currently involved in assessing if CF patients are having an 
exacerbation and deciding a treatment plan and computer literate with internet access 
available for the duration of the study.  
The stages of this Delphi survey are summarised in Figure 1. Ethical approval was 
obtained from the Office for Research Ethics Committees Northern Ireland. Research 
governance was sought at participating sites. Data collection took place over a seven month 
period (Sept 2010-April 2011). In each round non responders were followed up and sent 
weekly reminders to complete the survey.  
 
2.2 Delphi Round 0: Statement Generation  
  
The aim of Round 0 was to generate a list of statements for Round 1 of the Delphi survey. 
The first step in developing the Delphi survey for this study was to conduct a systematic 
literature search and extract criteria used to identify an exacerbation. This search identified 
218 criteria from 86 articles. However, there were many similarities in the terminology used, 
consequently criteria that were similar in meaning were grouped together to form one 
category. The list of 218 criteria was condensed to form 31 themes, which were then agreed 
by the research team.  
The themes were built on further through the results of patient interviews with 47 
adults with CF to identify their perception of the indicators of an exacerbation and a review of 
CF specific quality of life instruments [16, 26, 27]. While these questionnaires are assessing 
quality of life, they contain signs, symptoms and feelings that are related to people with CF 
and are used in clinical trials and in clinical practice to help identify the health status of 
patients which were not already covered by the themes identified.   
The agreed themes were used to formulate statements for “Round 1” of the Delphi 
survey. Finally, health professionals at the Belfast CF centre independently reviewed the 
statements.  A few minor changes were made. One issue related to haemoptysis that can 
have a range of severity levels . It was agreed that it should be represented as two separate 
statements: ‘Sputum streaked with blood’ and ‘Frank haemoptysis’ (referred to as ‘Coughing 
up blood’ in the adults with CF survey).  Although it was recognized that haemoptysis is not 
a particularly common feature of exacerbations in CF, clearly frank bleeding is of concern. 
The research team therefore agreed that inclusion of two statements were sufficient when 
considering this potential sign.  
The statements were then piloted with several adults with CF to ensure clarity of the 
wording. The research team recognise there is some overlap between some of the 
statements used in the Delphi survey, however, this was partly as a result of the feedback 
from the adults with CF. For example, they considered there was a distinction between the 
statements, “Feeling more short of breath than usual” and “Trouble breathing” and advised 
that they should remain as distinct statements. The adults with CF also provided their views 
on different response formats recommended for use in Delphi methodology in order to inform 
the preferred response format for this survey and to finalise the survey [22]. Two surveys 
with statements (n=48) focussing on indicators of PEX were compiled, one for adults with CF 
and one for CF health professionals. The only difference was in the use of lay terminology in 
the patient survey e.g. instead of haemoptysis “Sputum streaked with blood in sputum” was 
used.  
 
2.3 Delphi Round 1  
  
Two Delphi surveys were administered simultaneously using the web based survey 
tool ‘Survey Monkey’ [28]. Both participant groups were given the same survey in Round 1, 
the only difference being that, where appropriate, the terminology was provided in lay terms 
for the adults with CF. Participants were asked to rate their level of agreement with each 
statement using a five point Likert scale (strongly agree, agree, neither agree nor disagree, 
disagree, strongly disagree) with an additional option of “don’t know”. For example, 
participants were asked to indicate their agreement with the statement that “Feeling more 
tired than usual, is an important indicator of pulmonary exacerbation”. There was also an 
open question where participants were able to add additional criteria/items to avoid missing 
any important issues.   
 
2.4 Delphi Round 2  
  
In Round 2 statements from Round 1 that did not reach consensus (defined as 75% 
agreement), along with five additional statements identified from the open question were 
presented to both groups. In Round 2, the adults with CF survey contained 32 statements 
and the CF health professional survey contained 30 statements. Participants were also 
provided with a summary of the results from Round 1 for their participant group; this included 
their individual original response, the group response, and a summary chart showing the 
responses to that particular statement. Participants were asked to reconsider the statement 
again, taking into account the feedback of results from Round 1, and to re-rate their level of 
agreement with each statement. They were advised that they did not have to change their 
response if they did not wish to. There were five additional statements developed from the 
open question in Round 1 which were also presented as new statements using the original 
format from Round 1.  
 
2.5 Delphi Round 3  
  
In Round 3 participants were presented with statements that had reached 75% 
agreement in Round 1 or 2. Both surveys contained 35 statements (Adults with CF survey: 
31 statements along with four additional statements to rate that had only reached consensus 
in the health professionals survey; CF health professionals survey: 30 statements along with 
five additional statements to rate that had only reached consensus in the adults with CF 
survey). Participants were asked to rate the level of importance on a scale of one to 10, 
where one represented the lowest level of importance and ten represented the highest level 
of importance.  
 
 
2.6 Data analysis  
  
The data generated from each round was analysed with SPSS 17.0 using descriptive 
statistics. The data from each participant group was analysed separately. The researcher 
summarising the data from all rounds was blinded to the study participant’s identity. In order 
to identify which statements had reached consensus in Round 1 or Round 2 the percentage 
agreement and median response were calculated. In Delphi surveys the level of consensus 
is determined prior to initiating data collection, and this can vary depending on the topic 
being investigated.  A consensus level of 75% was selected following guidance from the 
literature; this meant including responses where a person had indicated that they ‘Strongly 
Agree’ or ‘Agree’ [21]. For Round 3 results were analysed by applying a rating average and 
then placing criteria in a ranked order of importance, in order to identify factors of importance 
within each group and to facilitate comparison between the groups.  
Further analysis was conducted in Round 3 to identify if the differences for individual 
statements between the groups were statistically significant, using the independent T-Test 
for statements with normally distributed data and the Mann Whitney U test was used for data 
which was not normally distributed. 
 
3. Results  
  
The CF centres that participated in this study were identified through the CF Trust 
website (www.cftrust.org.uk) and the CF Association of Ireland website (www.cfireland.ie). 
The centres were all specialist CF centres providing care for adults with CF. All 27 centres 
identified were invited to participate in the study and data was obtained from 13 (48%). Of 
the 14 centres that did not participate, seven declined due to a variety of reasons including 
commitments to other studies or staffing restraints, five did not respond, and two agreed 
initially but due to difficulties with their local research governance approval they were unable 
to take part.  
In Round 1, 31 adults with CF with moderate to severe disease completed the  
survey. The participants ranged from age 23 to 52 years. All participants confirmed that they 
had experienced at least 1 exacerbation in the previous year (defined by their centre) and 
were treated with IV antibiotics. The number of exacerbations reported by the adults with CF 
were 1-3 n=17; 4-6 n=11; >6 n=3. A lung function (FEV1%predicted) of less than 40% was 
reported by 11 participants and 8 participants reported a lung function of 40-60%. In Rounds 
2 and 3 the surveys were completed by 28 and 27 participants respectively.  
All 38 CF health professionals who registered completed all survey rounds. Their 
professions are as follows: nurse n=13, physiotherapist n=6, dietician n=1, doctor n=18. By 
the end of Round 2, 31 statements from adults with CF, and 30 statements from CF health 
professionals, had reached consensus (Figure 1). In Round 3 there were clear differences 
between adults with CF and CF health professionals as to the important indicators of an 
exacerbation. Tables 1 and 2 show the mean scores, standard deviation and rating order for 
all the statements (adults with CF and health professionals) from Round 3. Indicators from 
the adults with CF that were rated of higher importance were commonly rated lower by CF 
health professionals; for example, “An increase in symptoms at night” was rated higher by 
adults with CF (rank order 5) and lower by CF health professionals (rank order 29). 
Indicators from CF health professionals that were rated high were commonly rated lower by 
patients with CF; for example “Haemoptysis (blood streaked sputum)” was rated higher by 
CF health professionals (rank order 13) and lower by adults with CF (rank order 33).  
It is difficult to select a cut off point however; few statements were rated high by both 
groups. For example the top ten indicators from the adults with CF, six of these were not 
ranked in the top 10 by CF health professionals. In the top 10 indicators from the CF health 
professionals, six of these were not ranked in the top 10 by adults with CF. The four 
statements in the top 10 where there was agreement were “A large decrease in lung function 
(Greater than 10% FEV1)”, “Feeling more short of breath than usual”, “Producing more 
sputum than usual” and “More coughing than usual”. Although FEV1,  is an objective indicator 
it is perhaps not surprising that it appeared as the top item on the adults with CF list, since 
there is a big emphasis on this measurement in the clinic. Examination of the standard 
deviations for each of the indicators showed that there was reasonably good agreement for 
individual criteria, although there was a trend to a reduced level of consensus in the less 
highly rated criteria. Following analysis via the independent T-Test or Mann Whitney U, there 
were 15 statements in Tables 1 & 2 which showed a statistically significantly different rating 
with a p-value <0.05. While it is interesting to note results which were significantly different 
this was, of necessity, a semi-quantitative study. While a certain degree of importance can 
be placed on the statistical significance, the research team felt more importance should be 
placed on the clinical relevance which is detailed through the hierarchy of average rating 
scores for each group.   
 
 
4. Discussion 
This study has used a series of surveys, including an initial systematic analysis of the 
literature, to clarify what are the key criteria for identifying a PEX in CF. It has demonstrated 
that adults with CF and CF health professionals generally identify a different hierarchy of 
important indicators of PEX. In general, the important indicators identified by the adults with 
CF were more subjective than those identified by the health professionals, who preferred 
more objective clinical measurements (Tables 1 and 2). The importance of physiological 
measurements, such as oxygen saturation, to CF clinicians has recently been reported in a 
study using clinical vignettes to identify exacerbation criteria [18]. However, often the 
relationship between changes in physiological measurements and changes in symptoms and 
function in people with respiratory conditions are weak, and this may help to explain why 
patients have different criteria than health professionals.  
It is not surprising that the two groups identified different hierarchies of importance for 
the signs and symptoms since they have access to different information; the patients 
experience symptoms, whereas the health professionals observe or measure them, or rely 
on patient reporting whichever symptoms they think are relevant, possibly in response to 
specific questioning by the clinician. A more defined series of questions and/or tests might 
help to improve information gathering. The timing of when indicators of an exacerbation 
occur could also be relevant, as symptoms may be apparent to patients which later trigger 
the health professionals to evaluate with objective investigations. This highlights that CF 
health professionals should consider the signs and symptoms described by an adult with CF; 
this is especially pertinent when the patient indicates that a specific symptom is often a likely 
precursor to an exacerbation in their condition. 
 Currently available criteria-based definitions only capture some of the indicators that 
were rated important in our study [15]. For example, indicators such as “Feeling the need to 
do more airways clearance than usual” which were considered important by adults with CF 
in our study are not in current criteria. Also indicators in our study such as “Increased 
inflammatory markers” considered important by health professionals are not in the current 
criteria [15]. Other indicators of PEX such as the four that Adults with CF and CF health 
professionals agreed were important (Tables 1 and 2) are captured in current definitions. 
These variations represent the complexity involved in developing an agreed definition and 
resulting clinical tool(s) or research tool. However, attempting to define an exacerbation in 
CF continues to be relevant because the presence/absence of an exacerbation is  
recognised by EMA as an important end point [14].  
A single set of criteria may not be the most useful in defining an exacerbation in CF. 
It may be more accurate to identify an individual set of signs and symptoms of a PEX for 
each patient; the extent of the deviation from their “usual signs and symptoms‟ could then be 
used to identify an exacerbation. This could be valuable to enable patients to share their 
management with their health professional, and perhaps incorporate an action plan relating 
to monitoring usual symptoms and recognising the onset of an exacerbation. It could help 
clinical teams to standardise the criteria used for admission to hospital with an exacerbation 
and with decisions around commencing oral or IV antibiotics, or more intensive therapy. If 
the criteria were useful in establishing the severity of the exacerbation this could help with 
decisions around treatment delivered at home versus hospital. It could also have a research 
utility in assessing response of specific therapies in limiting the severity of exacerbations by 
bench marking efficacy against clearly identified personalised criteria for each individual 
patient. This is generally what CF clinicians do informally as part of clinical reasoning, and it 
would be helpful if this was formalised into a tool that could be used by patients at home and 
in clinical trials.  
Further research is required to build on the findings of this study. It is notable that the 
signs and symptoms that prompt adults with CF to seek medical attention are often different 
from those considered most important by the health professionals. Therefore, a dialogue 
between clinicians and patients should be encouraged to help individuals identify which 
signs and symptoms are critical for them in identifying the onset of a PEX. The aim would be 
to promote earlier engagement with their CF centre which could result in earlier intervention 
and triage of treatment options. The results of this study could also be used to explore if the 
criteria selected by CF health professionals provide scope for helping to determine treatment 
plans. A clinical tool may be an appropriate way forward. For example, the Chronic 
Respiratory Disease Questionnaire (CRDQ) enables patients to identify up to 5 activities 
which induce breathlessness; in the same way a clinical tool for defining PEX could consider 
5 (or more) criteria which individual patients select as important in defining their exacerbation 
[29].  A new tool could also incorporate objective indicators that health professionals 
consider important. For example, the Asthma Control Questionnaire incorporates patient’s 
views on whether their asthma is under control as well an objective measurement of Peak 
Respiratory Flow Rate [30]. Any new tool should consider that different indicators of a PEX 
may be associated with different degrees of disease severity and also different severity of 
exacerbation [16].  
  Despite the high response rate with 94% of participants completing all three rounds 
of the Delphi, a limitation of this study is the small sample size. However, we included a 
large spread of centres across the British Isles giving confidence that we obtained a 
representative range of experience from CF centres of different sizes and localities. In Delphi 
studies it is proposed that the consensus level be defined in advance of acquiring the data 
so that the researchers cannot influence the outcome of the survey [22]. We chose the 75% 
consensus level through reference to previously published Delphi studies but the choice of a 
specific consensus level is an aspect of Delphi methodology that remains contentious [22]. 
The validity of our study was optimised by providing explicit participant inclusion criteria, pilot 
testing, setting a predetermined consensus level, and monitoring the number of rounds [20-
23].  
 
5. Conclusions  
  
This study used a Delphi consensus method to ascertain important indicators of PEX 
from the perspectives of adults with CF and CF health professionals. There were clear 
differences in perspectives between the two groups in relation to the important indicators of 
an exacerbation in CF. 
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 Fig. 1. Summary of the stages of the Delphi surveys.  
Key. Health professionals: HPs, cystic fibrosis: CF. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 1.  
Indicators of an exacerbation from a Delphi survey in adults with CF: mean scores, standard 
deviation and rank order of each statement. 
Statement Mean score 
Std. 
deviation 
Rank 
order 
A large decrease in lung function (greater than 10% FEV1) 9.33 0.784 1a 
Feeling more short of breath than usual 8.52 1.087 2a 
Trouble breathing 8.52 1.805 2 
Feeling the need to do more airway clearance than usual 8.37 1.115 4 
An increase in symptoms at night 8.22 1.450 5 
Producing more sputum 8.19 1.388 6a 
Finding it harder than normal to do your usual exercise 7.96 1.581 7 
Finding it harder than normal to do your usual activities 7.93 1.838 8 
Feeling more exhausted than usual 7.85 1.703 9 
More coughing than usual 7.85 1.610 9a 
A change in the colour of your sputum 7.78 1.601 11 
More wheezing or chest tightness 7.7 1.815 12 
Feeling more fatigue than usual 7.59 1.760 13 
Generally feeling unwell 7.59 1.716 13 
Breathing at a faster rate than usual 7.48 1.805 15 
Thicker sputum than usual 7.44 2.082 16 
Less energy than usual 7.41 1.600 17 
Feeling more tired than usual 7.37 1.779 18 
Having to use more inhaled medications (i.e. inhalers, mucolytics) than 
usual 7.33 2.287 19 
Knowing you have an increase in the infection markers in your blood 
(for example CRP, white cell count) 7.33 2.201 19 
Knowing that your oxygen levels are low 7.33 2.130 19 
More chest pain than usual 7.33 2.434 19 
Coughing up blood 7.15 2.231 23 
Knowing that you have a decrease in your oxygen saturation 7.15 2.013 23 
(measured with a finger probe) 
Increased time spent resting 7.11 1.672 25 
Sputum that is harder to cough up 7.11 1.888 25 
Fever or increased temperature 7.07 2.183 27 
A change in the taste of your sputum 7.04 2.047 28 
Loss of appetite 6.93 1.859 29 
Knowing that you have new bacteria in your sputum 6.81 2.095 30 
Generally looking unwell 6.81 2.113 30 
Knowing that you have new additional breath sounds when your chest 
is examined 6.78 1.888 32 
Sputum streaked with blood 6.7 1.728 33 
Weight loss 6.59 1.947 34 
Knowing that you have new changes on chest x-ray 6.56 1.888 35 
 
Bold = the top 10 statements ranked. 
Note: Scores with the same average rating were given the same joint ranked position. 
      a - Also ranked in the top 10 by CF HPs. 
 
 
 
 
 
 
 
 
 
 
 
Table 2.  
Indicators of an exacerbation from a Delphi survey in CF health professionals: mean scores, 
standard deviation and rank order of each statement. 
Statement Mean score 
Std. 
deviation 
Rank 
order 
Increased sputum 8.84 1.027 1a 
A large decrease in lung function (greater than 10% FEV1) 8.84 1.263 1a 
More shortness of breath than usual 8.32 1.141 3a 
Increased inflammatory markers (for example CRP and 
white cell count) 7.92 1.124 4 
Fever or increased temperature 7.89 1.269 5 
Increased respiratory rate at rest 7.82 1.557 6 
Decreased oxygen saturation 7.79 1.510 7 
Hypoxia/hypoxemia 7.76 1.807 8 
Change in the colour of sputum 7.61 1.636 9 
New changes on chest X-ray 7.47 1.767 10 
Increased coughing 7.47 1.466 10a 
Trouble breathing 7.42 1.500 12 
Haemoptysis (blood streaked sputum) 7.34 1.760 13 
Decreased exercise tolerance 7.32 1.416 14 
Feeling the need to do more airway clearance than usual 7.21 1.379 15 
New added breath sounds on auscultation 7.08 1.807 16 
Frank haemoptysis (fresh blood) 7.08 2.306 16 
Increased thickness (viscosity) of sputum 7.05 1.559 18 
Having to use more inhaled medications (i.e. inhalers, 
mucolytics) than usual 7.03 1.197 19 
Difficulty performing usual activities 6.74 1.655 20 
Feeling more tired than usual 6.71 1.575 21 
Increased wheeze or chest tightness 6.66 1.419 22 
Difficulty clearing sputum 6.66 1.475 22 
Generally feeling unwell 6.63 1.601 24 
Feeling more fatigue 6.58 1.571 25 
Weight loss 6.5 1.928 26 
Feeling more exhausted than usual 6.47 1.640 27 
Decreased appetite 6.29 1.541 28 
Increased symptoms at night 6.26 1.884 29 
Lack of energy 6.24 1.532 30 
Chest pain 6.11 1.721 31 
Change in the taste of sputum 5.92 1.978 32 
Generally looking unwell 5.89 1.813 33 
Increased time spent resting 5.76 1.667 34 
New bacteria in sputum 5.5 2.153 35 
 
Bold = the top 10 statements ranked. 
Note: Scores with the same average rating were given the same joint ranked position. 
      a  -   Also ranked in the top 10 by adults with CF. 
 
